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Summary. Radioimmunoassays for erythropoietin 
are limited so far to a few specialized laboratories 
and this requires transport and storage of samples. 
We therefore tested the stability of immunoreactive 
erythropoietin serum and plasma samples ob- 
tained from a uremic and a nonuremic anemic pa- 
tient. No significant change in the concentration 
of immunoreactive erythropoietin was found in ei- 
ther serum or plasma samples for up to 14 days 
of storage. This type of stability was observed no 
matter whether the samples were stored at room 
temperature, 4 °C, or -20  ° C. There was no differ- 
ence between the estimates of erythropoietin  se- 
rum and heparinized plasma. Validity of the radio- 
immunoassay used in this study was demonstrated 
by parallelism of dilution curves of test specimens 
and the 2 na International Reference Preparation 
for erythropoietin and by a close correlation be- 
tween the immunoreactivity and the bioactivity of 
the hormone, as assessed in the same samples by 
the exhypoxic polycythemic mouse bioassay. 
In conclusion the data obtained clearly indicate 
that the necessity of storage and transport of clini- 
cal samples does not limit the practicability of the 
radioimmunoassay for erythropoietin. 
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Since recombinant human erythropoietin (rhEPO) 
became available for replacement therapy in pa- 
Abbreviations. BSA = bovine serum, albumin; EPO = erythro- 
poietin; i rEPO=immunoreact ive erythropoietin; IRP=Inter -  
national Reference Preparation; hct=hematocr i t ;  rhEPO=re-  
combinant human erythropoietin; RIA = radioimmunoassay 
tients with certain forms of anemia [5, 9], the deter- 
mination of erythropoietin (EPO) levels in body 
fluids has gained increasing clinical importance. 
However, radioimmunoassay kits are not yet com- 
mercially available and the limitation of EPO de- 
terminations to specialized laboratories necessi- 
tates storage and transport of the samples. This 
makes it important o know the stability of EPO 
in human samples. We therefore performed subse- 
quent radioimmunological determinations of EPO 
for up to 14 days on serum and plasma samples 
which were stored at room temperature, 4 ° C, or 
-20  ° C. The validity of RIA estimates was secured 
by determination of the biological activity of the 
same samples using an in vivo bioassay and by 
comparison of the slopes of dilution curves of test 
samples and the 2 nd International Reference Prepa- 
ration (IRP) for EPO. 
Material and Methods 
Antiserum to Erythropoietin 
Three New Zealand white rabbits were immunized 
with pure rhEPO (25 gg per animal) according to 
standard methods. EPO for immunization was ob- 
tained from Genetics Institute, Boston, USA. Dur- 
ing immunization two rabbits (# 1 and # 2) be- 
came severely anemic. Figure t shows the binding 
of radiolabelled recombinant human EPO to the 
different rabbit sera. It is obvious that rabbit # 1 
produced a high titer of antibodies against EPO. 
The serum of this animal was used for radioimmu- 
noassay. 
Radiolabelled Erythropoietin 
Human 3-(125I)iodotyrosyl-erythropoietin, pre-
pared by iodination of rhEPO using sodium 
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Fig. 1. Binding of recombinant human lzSI-EPO to sera of rabbits immunized against EPO. 100 ~tl serum at different dilutions 
was incubated with 100 ~tl x25I-EPO (containing 6000 cpm, i.e., 14 fmol EPO) at 4 ° C overnight. EPO bound to antibodies was 
precipitated using 100 btl (1 unit) of goat-anti-rabbit gammaglobulin 
(lzsI)iodide and chloramine T, with a specific ac- 
tivity of 320 to 620 Ci/mmol was purchased from 
Amersham International (Amersham, England). A 
dilution containing 8x10 11 mol radiolabelled 
EPO/1, corresponding to 6000-9000 cpm/100 I~1, 
was prepared for use in the RIA. 
Erythropoietin Standard 
The 2 "d International Reference Preparation (IRP) 
of human urinary EPO was obtained from the Bu- 
reau of Biological Standards, National Institute of 
Medical Research, London, England, and was 
used as standard in the RIA and the bioassay. 
Radioirnmunoassay for Erythropoietin 
Phosphate buffered saline, pH 7.5, containing 
0.1% bovine serum albumin (BSA) was used as 
diluent buffer for all reagents. All incubations were 
carried out at 4 ° C. 
Test Procedure. Aliquots of the following were 
combined in Eppendorf reaction cups: (a) 100 ~tl 
of plasma, serum, or standard solutions 
(10-500 mU EPO/ml), (b) 100 t~1 of diluted EPO 
antiserum (I :60000), and (c) 20 gl of 30% BSA 
in PBS. After preincubation for 24 h, 100 btl of ra- 
diolabelled EPO (8 x 10 -15 mol) was added and 
tubes were incubated for another 24 h. This de- 
layed addition of the tracer resulted in increased 
steepness and a leftward shift of the log dose-re- 
sponse curve (see below) compared to the simulta- 
neous addition of tracer with sample and antise- 
rum (50% binding at 65 mU/ml vs 250 mU/ml 
EPO) and thereby markedly increased sensitivity 
of the assay. This effect has been attributed to the 
formation of multivalent antigen-antibody com- 
plexes which are less likely to dissociate than uni- 
valent complexes [1]. After the incubation, separa- 
tion of bound vs free ligand was accomplished us- 
ing a secondary antibody technique. For this pur- 
pose 100 btl (1 unit) of goat-anti-rabbit-gamma- 
globulin (Calbiochem) and 100 btl rabbit gamma- 
globulin (0.03 rag; Calbiochem) were added to the 
Eppendorf reaction cups to precipitate bound li- 
gand. After incubation for 4 h the tubes were cen- 
trifuged at 9500 g for 15 rain. The supernatant was 
aspirated and the pellet counted for 125I radioac- 
tivity. 
Data Analysis. Data were expressed as percent of 
binding in the absence of unlabelled EPO. Calcula- 
tions of unknowns were made on the basis of a 
standard log dose-response curve derived by the 
"spline-function" method (LKB Wallac Compu 
Gamma RIA program 1282-114); (Fig. 2, right 
panel). 
Quality Controls. Protein bound radioactivity (as 
determined by adding 1 ml 10% TCA to a control 
tube before the last incubation) was about 90% 
of the radioactivity added. The maximum amount 
of antibody-precipitable 125I EPO (as determined 
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Fig. 2. Parallelism of erythropoietin-standard (2 "a IRP) dose-response curves and serial dilution curves of heparinized plasma 
(open symbols) and serum (closed symbols) from patient I (c3 : =) and patient 2 (a: A) in the exhypoxic polycythemic ouse bioassay 
(left panel) and radioimmunoassay (right panel). Data in the bioassay indicate mean __ S.E. of five animals each 
using 100 gl of diluent buffer instead of EPO stan- 
dard) was approximately 55% of the total radioac- 
tivity added. Nonspecific binding (as determined 
using 100 gl of diluent buffer instead of antiserum) 
was about 1% of the total radioactivity added. 
The intraassay coefficient of variation (assessed 
by tenfold determination f a diluted serum sample 
with a mean of 70.4 mU/ml) was 1.9%. The inter- 
assay coefficient of variation of 20 assays was 7.5 % 
and 6.8% for samples containing, respectively, a 
mean of 43.8 mU and 168.5 mU rhEPO. 
Bioassay for Erythropoietin 
The biological activity of EPO was measured by 
a modification of the exhypoxic polycythemic 
mouse bioassay [3]. Female ICR-strain mice 
(25-31 g) were exposed to intermittent (20-22 h/ 
day) normobaric hypoxia for 14 days, using a 
chamber that was gassed with a mixture of nitro- 
gen and normal atmospheric air. The resulting oxy- 
gen concentration i the chamber was 7%-8%. 
This regime renders animals everely polycythemic 
(hematocrit 80% on average) and leads to a subse- 
quent inhibition of endogenous erythropoiesis. 
On days 5 and 6 after removal from the 
chamber, assay animals were injected subcutane- 
ously with 0.5 ml of divided doses of standards 
or samples dissolved in 0.9% NaC1. On day 7 they 
were injected with 0.1 gCi 59Fe i.p. Two days later 
heparinized blood was obtained by heart puncture 
for determination of hematocrit (hct) and radioac- 
tive iron incorporation, which was calculated on 
the assumption of a blood volume of 7.5% body 
weight. The mean hct in the assay described was 
66.4% + 5.46% (mean _+ SD ; n = 105). Only mice 
having a hct of 55% or higher were used for the 
calculations. EPO content of samples was deter- 
mined on the basis of a standard log dose-response 
curve (Fig. 2, left panel), using the mean of five 
animals per point. In red blood cells of animals 
not receiving EPO 59Fe incorporation averaged 
0.47%. 
Sample Collection and Storage 
Two male anemic patients erved as blood donors. 
Patient 1 (hct 21%) was suffering t¥om aplastic 
anemia, patient 2 (hct 40%) was on hemodialysis 
because of chronic renal failure due to polycystic 
kidney disease. Venous blood samples of these two 
patients were collected into either plain or heparin- 
coated glass tubes and immediately kept on ice. 
Serum and plasma were separated in a refrigerated 
centrifuge and aliquotted under sterile conditions. 
The first RIA and estimation of EPO activity in 
the bioassay were performed within 2 h after col- 
lection of samples. The remaining aliquots were 
stored either at room temperature, at4 ° C, or fro- 
zen ( -20  ° C), and allowed to thaw only on the 
day of assay. Subsequent RIAs on serum and plas- 
ma stored under these different conditions were 
then performed aily up to day 6 and on days 
9 and 14 after collection. 
Results 
The serum levels of EPO determined in the bioas- 
say immediately after collection of the blood sam- 
ples were 4200 mU/ml in patient 1 and 546 mU/ml 
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Fig. 3. Results of subsequent RIA determinations of EPO on 
serum and plasma samples tored under different conditions 
in patient 2, the corresponding estimates in plasma 
were 4000 mU/ml (patient 1) and 618 mU/ml (pa- 
tient 2). Thus there was no significant difference 
between the biological activity of EPO in serum 
or plasma. 
The results of the first radioimmunological esti- 
mations of the serum and plasma samples, which 
were performed shortly after collection, were 
4520 mU/ml and 4068 mU/ml respectively in pa- 
tient 1 and 677 mU/ml and 682 mU/ml respectively 
in patient 2. The comparison between these results 
and the bioassay results shows a close correlation 
between the biological activity of the hormone and 
the immunoreactivity as assessed in the RIA, pro- 
viding good evidence for the validity of the latter. 
As documented in Fig. 2, high specificity of both 
the bioassay and the RIA was further reflected 
by identical slopes of dilution curves of the samples 
and the 2 na IRP of EPO, used as standard. 
Figure 3 shows the results of the subsequent 
RIAs, performed on aliquots of serum or plasma 
stored under sterile conditions for various time in- 
tervals at different temperatures. It is obvious, that 
in samples from both patients there was no signifi- 
cant change of the estimates of immunoreactive 
Or) EPO up to 14 days, no matter whether the 
samples were stored at room temperature, 4 ° C, 
or -20  ° . Furthermore, there was no significant 
difference between the estimates of irEPO in serum 
and plasma, either in individual assays, or compar- 
ing the means. The coefficient of variation of all 
determinations was 5.6% in patient 1 and 8.0% 
in patient 2 and this was within the normal imits 
of the assay. 
Discussion 
In order to determine the conditions that allow 
storage of human samples for valid determinations 
of irEPO, we tested the in vitro stability of irEPO 
in serum and plasma samples from a uremic and 
a nonuremic blood donor by subsequent RIAs. 
First we found no significant difference be- 
tween estimates of EPO in serum or heparinized 
plasma. This agrees with other investigators, who 
also compared RIA estimates of serum and plasma 
and found either equally no difference [4] or a mi- 
nor reduction of the mean recovery in heparinized 
plasma [2] or EDTA plasma [7]. For clinical pur- 
poses it is important hat heparinized plasma and 
serum can be used interchangeably in the EPO- 
RIA, as many candidates for EPO determinations 
are uremic patients, in whom blood samples are 
often collected at the occasion of hemodialysis and 
may contain various amounts of heparin. 
Second, we found that storage of the samples 
for up to 14 days even at room temperature did 
not significantly affect he amount of immunoreac- 
tive EPO. This finding does, of course, not exclude 
any minor changes in the molecular structure of 
the hormone. However, it demonstrates, that EPO 
is certainly not subjected to rapid proteolysis, as 
has been shown for some polypeptide hormones 
in biological fluids [10]. This complements pre- 
vious observations of a considerable stability of 
EPO under various other conditions, e.g., in re- 
sponse to heating [8], change in pH, or exposure 
to various chemicals [6]. 
We conclude from the high stability of irEPO 
in serum and plasma, that no special precautions 
such as addition of protease inhibitors are required 
for the preservation of the hormone content and 
that samples do not necessarily have to be frozen, 
as long as assaying is guaranteed within 2 weeks 
of collection. 
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